This study is testing whether combining two existing cancer drugs—pembrolizumab and lenvatinib—can help control recurrent clear cell ovarian cancer. The trial will enroll about 30 patients whose cancer has returned after prior treatment. Researchers will measure how well the comb…
Phase: PHASE2 • Sponsor: Elizabeth K. Lee MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC